Confidence In SpringWorks Grows With Expanded GSK Deal And Nirogacestat Plans
On Track For First Approval In 2023
SpringWorks is on course to bring nirogacestat to market by next year – and could play a pivotal role in making BCMA-targeting drugs a success.
You may also be interested in...
The DREAMM-3 study was meant to be a confirmatory study for Blenrep, and its failure raises concerns over its use in earlier lines of therapy and the possibility that it could be removed from the market.
The new company will focus mainly on Ayala’s lead candidate for desmoid tumors, but minority owner Advaxis will take over management.
Biopharma stock prices overall are trending down again, but standout firms are raising cash, including the first company to price an IPO over $100m since May, Third Harmonic. Also, Sarepta and Alnylam launched large note offerings, totaling $1bn and $900m, respectively.